Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Clinical trial NCT06298084 · RECRUITING

Trial details

NCT number

NCT06298084

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Status

RECRUITING

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2024-03-21

Primary completion

2027-09-01

Enrollment

152

View on ClinicalTrials.gov